Medical Watch Disease & Treatment News

Can engineered delivery systems make an immunologically cold colorectal-cancer subtype responsive to checkpoint therapy?

• Peptide coacervates...

Can biomarker diagnostics and early anti-amyloid therapies create a workable Alzheimer’s pathway?

• Roche’s blood/CSF tests target underdiagnosis (up...

Immune checkpoint inhibitors have transformed oncology by delivering durable responses in cancers previously refractory to systemic therapy.

A novel endogenous nanoparticle vaccine integrates self-assembling BP26 antigen with OMP16 epitopes to elicit protective immunity against Brucella. This self-assembling antigen-and-epitope approach could advance next-generation brucellosis vaccines.

ICI regimens improved overall survival in advanced ESCC for both first-line (HR 0.70) and later-line (HR 0.74) settings, yet none of 21 pooled...

The FDA-cleared PrecivityAD2 blood test delivers 97.6% positive predictive value and 93.1% negative predictive value for amyloid detection, matching...

A $1.5 million grant plus incubator support will let Ebivanta Therapeutics complete preclinical work and prepare its dual-targeted mRNA EBV vaccine...

Dual-targeting CAR T cells against both CD19 and CD22 achieved 99.2% complete remission in 308 heavily pretreated children with relapsed or refractory...

The FDA's approval of Ionis' zilganersen gives patients with Alexander disease—the first approved treatment for this rare genetic white-matter...

Cancer cells release the antioxidant enzyme PRDX1 to deplete reactive oxygen species that T cells require for activation, creating an...

The FDA's clearance of the first-in-human AAV9 gene-therapy trial for mucolipidosis type IV represents a major regulatory milestone for an ultra-rare...

Bacteria have evolved significant resistance to antibiotics decades after their introduction, driving the need for faster development of effective...

Could CDK2 inhibitors help overcome resistance to immune checkpoint blockade across many cancers?

• Mechanism: CDK2 hyperactivation suppresses immune...

China’s NMPA approved LEQEMBI SC-AI as the first at-home initiation option for early AD, offering once-weekly self-injection instead of bi-weekly IV...

PHENOGENE-1A opens a new front in Alzheimer's by combining neuroinflammation and amyloid targets with precision medicine, moving beyond amyloid-only approaches toward more personalized strategies.

• In the first trial of six patients with severe, treatment-resistant RA, three achieved sustained remission without medication for up to one year.
  -...

Rusfertide, a first-in-class hepcidin mimetic, could shift PV management by helping patients maintain hematocrit below 45% and cut phlebotomy needs,...

White paper shows outpatient CAR-T delivery is expanding via structured models, but success hinges on operational readiness rather than clinical...

Aptevo reported a 93% clinical benefit rate and 79% remission rate with mipletamig plus venetoclax/azacitidine in frontline TP53-mutated AML, far...

mRNA vaccine momentum validates neoantigen targeting in adjuvant melanoma settings, yet late-stage solid tumors face distinct resistance barriers that...